Fate Therapeutics (FATE) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Nvidia to commit $3 bln to Meta share offering as part of bigger AI partnership
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Boeing free cash flow beats estimates despite production challenges
Tweet
Share
E-mailGet Alerts FATE Hot Sheet
Join SI Premium – FREE
Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29).
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corning shares rise 3% in premarket trade after Q3 EPS, revenue beat estimates
- CTS Corp. (CTS) Tops Q3 EPS by 10c ; Offers Guidance
- PayPal lifts full-year profit guidance; Q3 revenue falls short
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
